Table 4. G6PD variants and corresponding G6PD activity in participants of the clinical trial and cross-sectional survey.
| G6PD variant | Parasitemia | Aparasitemia | p-Value | ||
|---|---|---|---|---|---|
| n (column percent) | Median G6PD activity in U/g Hb (IQR, minimum–maximum) | n (column percent) | Median G6PD activity in U/g Hb (IQR, minimum–maximum) | ||
| Microscopic parasitemia | |||||
| Mahidol homozygous | 2 (40.0) | 2.03 (0.02–4.03, 0.02–4.03) | 56 (53.3) | 0.51 (0.16–0.78, 0.00–13.06) | 0.448 |
| Mahidol heterozygous | 1 (20.0) | 5.38 (n = 1) | 42 (40.0) | 3.72 (2.06–4.85, 0.00–14.52) | 0.348 |
| Orissa homozygous | 1 (20.0) | 0.7 (n = 1) | 6 (5.7) | 2.77 (1.21–3.17, 0.27–4.19) | 0.285 |
| Orissa heterozygous | 1 (20.0) | 6.22 (n = 1) | 0 (0.0) | n = 0 | 0.045 |
| Kalyan–Kerala homozygous | 0 (0.0) | n = 0 | 1 (1.0) | 2.07 (n = 1) | 0.955 |
| Total | 5 (100.0) | — | 105 (100.0) | — | — |
| Submicroscopic parasitemia | |||||
| Mahidol homozygous | 3 (60.0) | 0.19 (0.00–1.53, 0.00–1.53) | 53 (53.0) | 0.53 (0.18–0.77, 0.00–13.06) | 1.00 |
| Mahidol heterozygous | 2 (40.0) | 2.59 (2.06–3.11, 2.06–3.11) | 40 (40.0) | 3.81 (2.09–4.96, 0.00–15.52) | 1.00 |
| Orissa homozygous | 0 (0.0) | — | 6 (6.0) | 2.77 (1.21–3.17, 0.27–4.19) | 1.00 |
| Kalyan–Kerala homozygous | 0 (0.0) | — | 1 (1.0) | 2.07 (n = 1) | 1.00 |
| Total | 5 | — | 100 | — | — |
G6PD, glucose-6-phosphate dehydrogenase; IQR, interquartile range.